1.0君实生物/en/新万博ManBetX客户端(中国百科)有限公司官网rich600338Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
/wp-content/uploads/2022/12/特瑞普利单抗-1-1024x683.png1024683SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Rxilient Biotech announced the collaboration on the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam. This collaboration is another significant milestone in toripalimab’s journey abroad. So far, toripalimab has been involved in overseas business activities in over 30 countries, spanning across North America, the Middle East, North Africa and South East Asia.